The state of Indiana currently has 11 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Josephson Wallack Munshower Neurology P.C, Indianapolis, Indiana
Conditions: Relapsing Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/15/2024
Locations: Neuroscience Institute Center Site Number : 8400053, Merrillville, Indiana
Conditions: Multiple Sclerosis
Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab
Recruiting
The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2024
Locations: TG Therapeutics Investigational Trial Site, Indianapolis, Indiana
Conditions: Relapsing Multiple Sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/08/2024
Locations: Neuroscience Institute Center Site Number : 8400053, Merrillville, Indiana
Conditions: Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/07/2024
Locations: Allied Physicians, Inc. ., Fort Wayne, Indiana
Conditions: Relapsing Multiple Sclerosis
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Recruiting
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/30/2024
Locations: Indiana University Health Neuroscience Center, Adult Neurology Center, Indianapolis, Indiana
Conditions: Relapsing Remitting Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Recruiting
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/24/2024
Locations: Methodist Hospital Site Number : 8400164, Merrillville, Indiana
Conditions: Primary Progressive Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/22/2024
Locations: Methodist Neuroscience Institute, Merrillville, Indiana
Conditions: Relapsing Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
Recruiting
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS) (Part 1), and to evaluate the effects of BIIB091 combination therapy with Diroximel Fumarate (DRF) compared with the DRF monotherapy arm, on the key Magnetic Resonance Imaging (MRI) measure of active Central Nervous System (CNS) inflammation (Part 2). The secondary objectives are to evaluate the effects of BIIB091 monotherapy on the MRI measures of... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/16/2024
Locations: Fort Wayne Neurological Center, Fort Wayne, Indiana
Conditions: Relapsing Forms of Multiple Sclerosis
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
Recruiting
The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Det... Read More
Gender:
All
Ages:
Between 30 years and 65 years
Trial Updated:
03/14/2024
Locations: Craig E. Herrman, Indianapolis, Indiana
Conditions: Multiple Sclerosis
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
Recruiting
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/09/2023
Locations: Rehabilitation Hospital of Indiana, Indianapolis, Indiana
Conditions: Multiple Sclerosis